SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
Quarterly Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
For the Quarter Ended March 31, 1996
Commission File No. 0-26288
CONTOUR MEDICAL, INC.
------------------------------------------------------
(Exact Name of Registrant as Specified in its Charter)
Nevada 77-0163521
- ------------------------------ ----------------------------------
(State or Other Jurisdiction of (IRS Employer Identification Number)
Incorporation or Organization)
3340 Scherer Drive
St. Petersburg, Florida 33716
----------------------------------------
(Address of Principal Executive Offices)
(813) 572-0089
----------------------------------------------------
(Registrant's Telephone Number, Including Area Code)
Indicate by check mark whether the Registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the Registrant was
required to file such report(s), and (2) has been subject to such filing
requirements for the past 90 days.
Yes [ X ] No [ ]
There were 5,214,223 shares of the Registrant's $.001 par value Common Stock
outstanding as of March 31, 1996.
CONTOUR MEDICAL, INC.
FORM 10-Q
INDEX
-----
Part I. Financial Information
- ------ ---------------------
Item 1. Financial Statements Page
Consolidated Balance Sheets as of March 31, 1996
and June 30, 1995 3-4
Consolidated Statements of Operations for the Three
and Nine Months Ended March 31, 1996 and 1995 5-6
Consolidated Statement of Stockholder's Equity
for the Nine Months Ended March 31, 1996 7
Consolidated Statements of Cash Flows for the
Nine Months Ended March 31, 1996 and 1995 8-9
Notes to Consolidated Financial Statements 10-13
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations 13-15
Part II. Other Information
- ------- -----------------
Item 1. Legal Proceedings 15
Item 2. Changes in Securities 15
Item 3. Defaults Upon Senior Securities 15
Item 4. Submission of Matters to a Vote of Security Holders 16
Item 5. Other Information 16
Item 6. Exhibits and Reports on Form 8-K 16
Signatures 17
CONTOUR MEDICAL, INC. AND SUBSIDIARIES
Consolidated Balance Sheets
March 31, June 30,
1996 1995
------------ ----------
(Unaudited)
ASSETS
Current:
Cash $ 68,717 $ 96,235
Accounts receivable - trade
Related parties (Note 4) 1,584,209 943,094
Other 2,324,721 760,703
Inventories (Note 5) 2,792,021 1,297,394
Refundable income taxes 10,680 10,680
Prepaid expenses and other 144,843 74,319
Due from parent (Note 4) 613,563 1,168,901
----------- ----------
Total Current Assets 7,538,754 4,351,326
Property and Equipment, less
accumulated depreciation (Note 6) 1,012,150 592,243
Other Assets:
Goodwill 1,351,321 --
Deposit on equipment 355,454 228,282
Other 302,863 4,575
----------- ----------
Total Other Assets 2,009,638 232,857
$10,560,542 $5,176,426
See accompanying notes to consolidated financial statements.
CONTOUR MEDICAL, INC. AND SUBSIDIARIES
Consolidated Balance Sheets
March 31, June 30,
1996 1995
------------- -----------
(Unaudited)
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Notes payable to banks -
credit lines (Note 7) $ 1,097,200 $ 245,600
Accounts payable 1,842,547 882,524
Accrued expenses 266,903 80,977
Current maturities of long-term
debt (Note 8) 295,843 168,477
---------- ----------
Total Current Liabilities 3,502,493 1,377,578
Long-term debt, less current
maturities (Note 8) 1,369,234 907,711
---------- ----------
Total Liabilities 4,871,727 2,285,289
Stockholders' Equity:
Preferred stock - Series A conver-
tible, $.001 par value, shares
authorized 1,265,000; issued
600,000, at aggregate liquidation
preference 2,400,000 2,400,000
Common stock $.001 par - shares
authorized 76,000,000; issued
5,214,223 and 4,802,280 (net of
$765 discount) 4,449 4,037
Additional paid-in capital 3,175,418 781,509
Retained earnings (Deficit) 108,948 (294,409)
---------- ----------
Total stockholders' equity 5,688,815 2,891,137
$10,560,542 $5,176,426
See accompanying notes to consolidated financial statements.
CONTOUR MEDICAL, INC. AND SUBSIDIARIES
Consolidated Statements of Operations
Three Months Ended
March 31, March 31,
1996 1995
------------ ------------
(Unaudited) (Unaudited)
SALES $3,779,566 $1,358,462
COST OF SALES 2,751,524 842,246
GROSS PROFIT 1,028,042 516,216
OPERATING EXPENSES 775,212 454,689
OTHER INCOME (EXPENSE) 10,031 1,188
---------- ----------
INCOME BEFORE INCOME TAXES 262,861 62,715
INCOME TAX EXPENSE 89,373 --
---------- ----------
NET INCOME $ 173,488 $ 62,715
NET INCOME PER COMMON SHARE $ .03 $ .01
WEIGHTED AVERAGE NUMBER OF COMMON
SHARES 4,967,739 5,220,799
See accompanying notes to consolidated financial statements.
CONTOUR MEDICAL, INC. AND SUBSIDIARIES
Consolidated Statements of Operations
Nine Months Ended
March 31, March 31,
1996 1995
---------- ----------
(Unaudited) (Unaudited)
SALES $8,529,915 $3,375,007
COST OF SALES 6,171,863 2,143,321
GROSS PROFIT 2,358,052 1,231,686
---------- ----------
OPERATING EXPENSES 1,760,156 1,244,429
OTHER INCOME (EXPENSE) 13,251 (45,912)
---------- ----------
INCOME (LOSS) BEFORE INCOME TAXES 611,147 (58,655)
INCOME TAX EXPENSE 207,790 --
---------- ----------
NET INCOME (LOSS) $ 403,357 $ (58,655)
NET INCOME (LOSS) PER COMMON SHARE $ .07 $ (.01)
WEIGHTED AVERAGE NUMBER OF COMMON
SHARES 4,885,602 4,520,799
See accompanying notes to consolidated financial statements.
CONTOUR MEDICAL, INC. AND SUBSIDIARIES
Consolidated Statement of Stockholders' Equity
Additional Retained
Common Stock Paid-in Earnings
Shares Amount Capital (Deficit)
--------- ------ ---------- ---------
Balance, June 30, 1995 4,802,350 $4,037 $ 781,509 ($294,409)
Exercise of common stock
options 26,250 26 49,974 --
Correction of prior conver-
sions of preferred stock 16,004 16 (16) --
Gain on sale of stock owned
by stockholder -- -- 36,531 --
Acquisition of AmeriDyne
Corporation 369,619 370 2,099,630 --
Tax benefit from utilization
of net operating loss
carryforward -- -- 207,790 --
Net income -- -- -- 403,357
Balance, March 31, 1996 5,214,223 $4,449 $3,175,418 $108,948
See accompanying notes to consolidated financial statements.
CONTOUR MEDICAL, INC. AND SUBSIDIARIES
Consolidated Statements of Cash Flows
Nine Months Ended
March 31, March 31,
1996 1995
---------- ----------
(Unaudited) (Unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss) $ 403,357 $ (58,655)
Adjustments to reconcile net income
(loss) to net cash provided (used) by
operating activities:
Depreciation 111,863 79,484
Tax benefit from NOL 207,790 --
Changes in assets and liabilities
net of effects from acquisition
of AmeriDyne:
(Increase) decrease in accounts
receivable (825,785) (325,238)
(Increase) decrease in inventories (234,060) (159,058)
(Increase) decrease in other
current assets and other assets (5,837) 91,245
Increase (decrease) in accounts
payable 290,257 471,735
Increase (decrease) in accrued
expenses and other liabilities 61,239 (59,308)
----------- ----------
Net cash provided by operating
activities 8,824 40,205
CASH FLOW FROM INVESTING ACTIVITIES:
Acquisition of equipment (549,017) (196,471)
Decrease in due from parent 555,338 (165,000)
Acquisition of AmeriDyne, net of
cash acquired (322,297) --
----------- ---------
Net cash used by investing
activities (315,976) (361,471)
See accompanying notes to consolidated financial statements.
CONTOUR MEDICAL, INC. AND SUBSIDIARIES
Consolidated Statements of Cash Flows
Nine Months Ended
March 31, March 31,
1996 1995
------------ ------------
(Unaudited) (Unaudited)
CASH FLOWS FROM FINANCING ACTIVITIES:
Deferred offering costs $ -- $ (55,767)
Net borrowing (payments) on loans 193,103 (32,254)
Proceeds from exercise of options 50,000 47,794
Payment of short-swing liability
by shareholder 36,531 --
Proceeds from issuance of stock -- 2,204,000
---------- ----------
Net cash provided by financing
activities 279,634 2,163,773
---------- ----------
NET INCREASE (DECREASE) IN CASH (27,518) 1,842,507
CASH BEGINNING OF PERIOD 96,235 56,998
---------- ----------
CASH END OF PERIOD $ 68,717 $1,899,505
SUPPLEMENTAL DISCLOSURE OF CASH
FLOW INFORMATION AND NON-CASH
ACTIVITIES:
Cash paid for interest $ 109,168 $ 37,938
Cash paid for income tax $ 930 $ --
See accompanying notes to consolidated financial statements.
CONTOUR MEDICAL, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements (Unaudited)
1. BASIS OF PRESENTATION
---------------------
The accompanying unaudited condensed financial statements have been
prepared in accordance with generally accepted accounting principles for
interim financial information. Accordingly, they do not include all of the
information and footnotes required by generally accepted accounting principles
for complete financial statements. In the opinion of management, all
adjustments, consisting of normal recurring accruals, considered necessary for
a fair presentation have been included. It is suggested that these condensed
financial statements be read in conjunction with the financial statements and
notes thereto included in the June 30, 1995, audited financial statements for
Contour Medical, Inc. The results of operations for the periods ended March
31, 1996 and 1995 are not necessarily indicative of the operating results for
the full year.
The consolidated financial statements include the accounts of Contour
Medical, Inc. ("CMI") and its wholly-owned subsidiaries, Contour Fabricators,
Inc. ("CFI"), Contour Fabricators of Florida, Inc. ("CFFI") and, since March
1, 1996, AmeriDyne Corporation ("AmeriDyne"), collectively referred to as the
Company. All material intercompany accounts and transactions have been
eliminated. CMI is a majority-owned subsidiary of Retirement Care Associates,
Inc. ("Parent").
On March 1, 1996,Contour Medical, Inc. acquired AmeriDyne through a
merger which was accounted for as a purchase. The Company issued 369,619
shares of its common stock and paid $250,000 to the sole stockholder of
AmeriDyne in connection with this purchase.
2. EARNINGS (LOSS) PER SHARE
-------------------------
Earnings (loss) per common share are based on the weighted average number
of common shares outstanding during each period after giving effect to a
1.05-for-1 forward stock split which occurred in March 1996. Common stock
equivalents have not been included since the effect would be antidilutive.
Cumulative dividends in arrears of $24,000, $72,000 and $8,000 related to the
Company's Series A preferred stock have been deducted from net income for the
three months ended March 31, 1996, nine months ended March 31, 1996 and three
and nine months ended March 31, 1995, respectively.
3. CHANGE IN YEAR END
------------------
The Company changed its fiscal year end from December 31 to June 30
during 1995.
4. RELATED PARTY TRANSACTIONS
--------------------------
During 1995, the Company began distributing medical supplies to health
care facilities owned, leased or managed by the Parent. Sales to these
facilities approximated $1,582,000 for the three month period ended March 31,
1996, and $3,235,000 for the nine month period then ended. Trade accounts
receivable of $1,584,209 and $943,094 were outstanding as of March 31, 1996
and June 30, 1995, respectively, as related to these health care facility
sales. Additionally, the Company had an outstanding loan receivable due from
its parent company of $613,563 and $1,168,901 as of March 31, 1996 and June
30, 1995, respectively, which is due on demand with no stated interest rate.
5. INVENTORIES
-----------
Inventories are summarized as follows:
March 31, June 30,
1996 1995
---------- ----------
Raw Materials $ 297,281 $ 259,952
Work in process 100,986 58,704
Finished goods 2,393,754 978,738
---------- ----------
$2,792,021 $1,297,394
All inventories are pledged as collateral (see Notes 7 and 8).
6. PROPERTY AND EQUIPMENT
----------------------
Property and equipment consist of the following:
March 31, June 30,
Useful Lives 1996 1995
------------ ---------- ----------
Land -- $ 50,000 $ 50,000
Building 5-45 years 596,247 596,247
Machinery and equipment 3-7 years 1,574,756 1,034,568
Furniture and fixtures 5-7 years 129,107 124,651
Leasehold improvements 5 years 181,422 13,923
Vehicles 3-5 years 58,745 9,109
---------- ----------
2,590,277 1,828,498
Less accumulated depre-
ciation 1,578,127 1,236,255
---------- ----------
$1,012,150 $ 592,243
All property and equipment are pledged as collateral (see Notes 7 and 8).
7. NOTES PAYABLE TO BANKS
----------------------
Notes payable to banks consists of the following:
March 31, June 30,
1996 1995
---------- ---------
Borrowings under CMI's and CFFI's $350,000
lines of credit, interest at prime plus 1%
(10% and 9.75% at June 30 and March 31,
1996, respectively), payable monthly,
collateralized by accounts receivable
and inventory $ 328,800 $245,600
Borrowings under AmeriDyne's credit
line of $975,000, interest at the bank's
prime plus 1.25% (9.5% at March 31, 1996),
payable monthly, collateralized by all the
Company's assets 768,400 --
---------- --------
$1,097,200 $245,600
8. LONG-TERM DEBT
--------------
Long-term debt consists of the following:
March 31, June 30,
1996 1995
---------- ----------
Mortgage payable to bank, bearing interest
at 8.58%, principal and interest of $6,793,
due monthly through 2003, collateralized by
accounts receivable, inventory, equipment
and real property $ 402,678 $ 491,622
Mortgage payable to bank, interest at prime
plus .75% (9.75% and 9.5% at June 30, 1995
and March 31, 1996, respectively), principal
of $1,190 plus interest due monthly through
2000, collateralized by accounts receivable,
inventory, equipment and real property 69,047 78,571
Note payable to bank, interest at prime plus
.75% (9.75% and 9.5% at June 30, 1995 and
March 31, 1996, respectively), principal and
interest of $3,044 due monthly through May
2000, collateralized by accounts receivable,
inventory, equipment and real property 465,365 182,622
Note payable to bank, interest at prime plus
1% (10% and 9.75% at June 30, 1995 and
March 31, 1996, respectively), principal of
$5,000 plus interest due monthly through
June 2000, collateralized by equipment 255,000 300,000
Note payable to bank, interest at prime plus
1% (10% and 9.75% at June 30, 1995 and March
31, 1996, respectively), principal and
interest of $1,667 due monthly through
August 1996, collateralized by accounts
receivable, inventory and equipment 10,000 23,333
Union Planters Bank of Jackson, Tennessee
payable in monthly installments of $3,600
including interest at 9.0% and maturing May
15, 1997. Collateralized by all of the
Company's assets 48,696 --
Union Planters Bank of Jackson, Tennessee
payable in monthly installments of $5,266
including interest at 9.0% and maturing
October 12, 1997. Collateralized by all of
the Company's assets 223,349 --
Capital lease-G.E. Capital payable in
monthly installments of $205, plus sales
tax. Interest imputed at 5.39% and
maturing April 1996. Collateralized by
Canon copier. 204 --
Capital lease-Eaton Financial Corporation
payable in monthly installments of $309,
plus sales tax. Interest imputed at 14.6%
and maturing June 1997. Collateralized by
computer equipment. 3,744 --
Delta Handling Materials, Inc. note payable
in 36 monthly installments of $533 including
interest at 11.0% and maturing December 1997.
Collateralized by Clark lift truck. 10,575 --
Note payable-stockholder Scott F. Lochridge.
Payable in 36 monthly installments of $5,693
including interest at 10.0%. Unsecured. 176,419 --
---------- ----------
1,665,077 1,076,18?
Less current portion 295,843 168,477
---------- ----------
Total long-term debt $1,369,234 $ 907,711
The net book value of property and equipment collateralized under the
above debt agreements was $1,012,150 and $592,243 as of March 31, 1996 and
June 30, 1995, respectively.
Certain of the above agreements contain certain financial and operating
covenants, including requirements that the Company maintain certain net worth
levels and satisfy current and debt-to-net-worth ratios. The Company was in
compliance with all debt covenants as of March 31, 1996 and June 30, 1995.
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS.
The following should be read in conjunction with the attached Financial
Statements and Notes thereto of the Company.
THREE MONTHS ENDED MARCH 31, 1996 COMPARED TO THREE MONTHS ENDED MARCH 31,1995
- -----------------------------------------------------------------------------
As a result of the factors discussed below, for the three months ended
March 31, 1996, the Company had net income of $173,488 compared to $62,715 for
the three months ended March 31, 1995.
Sales increased by $2,421,104 for the three months ended March 31, 1996
as compared to the three months ended March 31, 1995. Approximately $180,000
of this increase related to an increase in demand for the Company's
traditional product lines and approximately $896,000 of the increase resulted
from sales by the Company's new subsidiary, AmeriDyne, acquired on March 1,
1996. Approximately $1,346,000 of the sales increase is attributed to sales
of bulk medical supplies and pre-packaged kits to nursing homes owned, leased
or managed by the Company's parent. These sales, which started during March
1995, represent a new market for the Company. Approximately $148,000 of these
nursing home sales represent sales of the Company's pre-packaged kits and the
remainder of the nursing home sales represents sales of bulk medical supplies.
The Company expects continued growth in sales to nursing homes of bulk medical
supplies and kits as the Parent expands the number of nursing homes it manages
or operates.
Gross profit for the three months ended March 31, 1996, was $1,028,042 or
27% of sales, as compared to $516,216 or 38% of sales, for the same period of
the previous year. The decrease in gross profit as a percentage of sales is
primarily due to the fact that pre-packaged kits and bulk medical supply
products have lower gross profit margins.
Operating expenses for the three month period ending March 31, 1996, were
$775,212 as compared to $454,689 in 1995. Operating expenses increased
$166,800 as a result of the operating expenses of the AmeriDyne subsidiary and
$153,723 as a result of higher administrative and marketing costs due to the
increased level of sales and overall business activity.
NINE MONTHS ENDED MARCH 31, 1996, COMPARED TO NINE MONTHS ENDED MARCH 31, 1995
- ------------------------------------------------------------------------------
As a result of the factors discussed below, for the nine months ended
March 31, 1996, the Company had net income of $403,357 compared to a net loss
of $(58,655) for the nine months ended March 31, 1995.
Sales increased $5,154,908 for the nine months ended March 31, 1996, as
compared to 1995. Approximately $690,000 of this increase was due to
increased demand for the Company's traditional product lines and approximately
$570,000 of the increase resulted from sales of pre-packaged kits and bulk
medical supplies to customers other than nursing homes, and approximately
$896,000 of the increase resulted from the AmeriDyne acquisition.
Approximately $2,999,000 of the sales increase was attributed to sales of bulk
medical supplies and pre-packaged kits to nursing homes owned, leased or
managed by the Company's Parent. Approximately $330,000 of these nursing home
sales represent sales of the pre-packaged kits and the remainder of $2,669,000
represents sales of bulk medical supplies to the nursing homes.
Gross profit for the nine months ended March 31, 1996, was $2,358,052 or
28% of sales, as compared to $1,231,686 or 37% of sales, for the same period
of the previous year. The decrease in gross profit as a percentage of sales
is primarily due to the fact that pre-packaged kits and bulk medical supply
products have lower gross profit margins.
Operating expenses for the nine month period ending March 31, 1996, were
$1,760,156 as compared to $1,244,429 in 1995. The operating expenses
increased by approximately $348,900 as the result of higher administrative and
marketing costs due to the increased level of sales and overall business
activity, and approximately $166,800 of the increase resulted from the new
AmeriDyne subsidiary.
LIQUIDITY AND CAPITAL RESOURCES
- -------------------------------
At March 31, 1996, the Company had $4,036,261 of working capital as
compared to $2,973,748 on June 30, 1995. The increase was primarily a result
of the acquisition of the AmeriDyne subsidiary.
Operating activities for the nine months ended March 31, 1996, provided
cash of $8,824 as compared to operating activities during the nine months
ended March 31, 1995, which provided cash of $40,205.
Inventories increased by approximately $234,000 from June 30, 1995 to
March 31, 1996, as a result of increased inventory levels needed to serve the
growing nursing home market. Accounts receivable and accounts payable have
increased due to the increased level of sales and inventories.
Cash flows from investing activities used cash of $315,976 during the
nine months ended March 31, 1996, as a result of the repayment of $555,338
from the Company's parent which was offset by the use of $549,017 for the
acquisition of additional equipment and $322,297 for the AmeriDyne
acquisition.
Cash flow of $279,634 was provided from financing activities in fiscal
1996 versus $2,163,773 in 1995. During the nine months ended March 31, 1996,
$193,103 was provided from net bank borrowings, $50,000 was provided by the
exercise of stock options, and $36,531 was provided by payment of a
short-swing liability by a shareholder.
The Company currently maintains a total of $1,325,000 in lines of credit
with its banks for short-term working capital needs. As of March 31, 1996,
$1,097,200 had been borrowed against these lines. Management believes that
the Company's working capital, together with anticipated net income from
operations and unused lines of credit, will be adequate to meet the Company's
needs for liquidity for at least the next twelve months. If additional
short-term capital is needed, management believes that the Company's Parent
would pay down the amount it owes to the Company.
The Company presently has no commitments for material capital
expenditures.
On March 1, 1996, the Company acquired AmeriDyne Corporation, a bulk
medical supply company located in the Southeast. In connection with this
agreement, the Company issued 369,619 shares of its Common Stock equal in
value to $2,100,000 and paid $300,000 in cash.
AmeriDyne Corporation has annual revenues of approximately $10,000,000.
SEASONALITY AND INFLATION
- -------------------------
The Company's business is relatively consistent and stable on a monthly
basis, and has not indicated any seasonality over the prior three fiscal
periods.
In addition, the Company does not believe that inflation has had a
material effect on its results from operations during the past three fiscal
years. There can be no assurance, however, that the Company's business will
not be affected by inflation in the future.
PART II. OTHER INFORMATION
Item 1. Legal Proceedings.
None.
Item 2. Changes in Securities
None.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Submission of Matters to a Vote of Security Holders
On February 29, 1996, the Company held an Annual Meeting of
Shareholders at which Chris Brogdon, Edward E. Lane and Darrell C. Tucker were
elected to serve as Directors of the Company, and BDO Siedman, LLP was
ratified as the Company's auditors. No other matters were presented for a
vote at the meeting.
The following sets forth the votes cast for and withheld in the
election of the Directors. There were no broker non-votes.
Nominees For Withheld
------------------ --------------- -----------
Gerald J. Flanagan 4,451,866 Votes 1,445 Votes
Chris Brogdon 4,451,866 Votes 1,445 Votes
Edward E. Lane 4,451,866 Votes 1,445 Votes
Darrell C. Tucker 4,451,866 Votes 1,445 Votes
The following sets forth the votes cast for, against and abstentions
on the ratification of BDO Seidman, LLP as the Company's auditors. There were
no broker non-votes.
Proposal submitting to vote For Against Abstain
-------------------------------- --------- ------- -------
Ratification of BDO Seidman, LLP 4,429,940 945 22,426
Item 5. Other Information
Effective April 2, 1996, Donald F. Fox became the President,
Treasurer and Chief Financial Officer of the Corporation. Gerald F. Flanagan,
who had held these positions, relinquished such positions on that date. Mr.
Flanagan continues to serve as the President of the Company's Florida and
Michigan subsidiaries.
Item 6. Exhibits and Reports on Form 8-K
(a) Exhibits: None.
(b) Reports on Form 8-K:
The Company filed a Report on Form 8-K dated March 1, 1996 reporting
information under Item 2 - Acquisition or Disposition of Assets of Form 8-K,
concerning the acquisition of AmeriDyne Corporation.
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934,
the Registrant has duly caused this Report to be signed on its behalf by the
undersigned thereunto duly authorized.
CONTOUR MEDICAL, INC.
Date: May 13, 1996 By /s/ Donald F. Fox
Donald F. Fox,
President, Treasurer and
Chief Financial Officer
EXHIBIT INDEX
EXHIBIT METHOD OF FILING
- ------- ------------------------------
27. Financial Data Schedule Filed herewith electronically
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from the
balance sheets and statements of operations found on pages 3-5 of the
Company's Form 10-Q for the year to date, and is qualified in its entirety by
reference to such financial statements.
</LEGEND>
<CIK> 0000829649
<NAME> CONTOUR MEDICAL, INC.
<PERIOD-TYPE> 9-MOS
<FISCAL-YEAR-END> JUN-30-1995
<PERIOD-END> MAR-31-1996
<CASH> 68,717
<SECURITIES> 0
<RECEIVABLES> 3,908,930
<ALLOWANCES> 0
<INVENTORY> 2,792,021
<CURRENT-ASSETS> 7,538,754
<PP&E> 2,590,277
<DEPRECIATION> 1,578,127
<TOTAL-ASSETS> 10,560,542
<CURRENT-LIABILITIES> 3,502,493
<BONDS> 0
<COMMON> 4,449
0
2,400,000
<OTHER-SE> 3,284,366
<TOTAL-LIABILITY-AND-EQUITY> 10,560,542
<SALES> 8,529,915
<TOTAL-REVENUES> 8,543,166
<CGS> 6,171,863
<TOTAL-COSTS> 6,171,863
<OTHER-EXPENSES> 1,760,156
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> 611,147
<INCOME-TAX> 207,790
<INCOME-CONTINUING> 0
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 403,357
<EPS-PRIMARY> .07
<EPS-DILUTED> .07
</TABLE>
